p53-dependent repression of polo-like kinase-1 (PLK1)

Cell Cycle

Volumn 9, Issue 20, 2010, Pages 4200-4212

  McKenzie, Lynsey ^a   King, Sharon ^a   Marcar, Lynnette ^a   Nicol, Sam ^a   Dias, Sylvia S ^a   Schumm, Katie ^a   Robertson, Pamela ^a   Bourdon, Jean Christophe ^a   Perkins, Neil ^a   Fuller Pace, Frances ^a   Meek, David W ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

DNA damage response; p53; PLK1; Repression

Indexed keywords

CISPLATIN; ETOPOSIDE; HISTONE DEACETYLASE; POLO LIKE KINASE 1; PROTEIN P21; PROTEIN P53; RENILLA LUCIFERIN 2 MONOOXYGENASE; TRICHOSTATIN A;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL STRAIN HCT116; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REPORTER GENE; RNA INTERFERENCE;

EID: 77958470977     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.20.13532     Document Type: Article

References (49)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749-58.
2. Vousden KH, Lane DP. p53 in health and disease. Nat Rev 2007; 8:275-83.
3. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31.
4. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1:a001883.
5. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12. (Pubitemid 351574202)
6. 2/M transition by p53. Oncogene 2001; 20:1803-15.
7. 2/M promoters. Mol Cell Biol 2005; 25:3737-51.
8. Martin BT, Strebhardt K. Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle 2006; 5:2881-5. (Pubitemid 44953940)
9. Saint Clair S, Manfredi JJ. The dual specificity phosphatase Cdc25C is a direct target for transcriptional repression by the tumor suppressor p53. Cell Cycle 2006; 5:709-13.
10. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10:265-75.
11. Fenton B, Glover DM. A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature 1993; 363:637-40. (Pubitemid 23227626)
12. Glover DM, Hagan IM, Tavares AA. Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998; 12:3777-87.
13. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30.
14. Yim H, Erikson RL. Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol 2009; 29:2609-21.
15. Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994; 107:1509-17. (Pubitemid 24198470)
16. Hamanaka R, Smith MR, O'Connor PM, Maloid S, Mihalic K, Spivak JL, et al. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem 1995; 270:21086-91.
17. Lee KS, Yuan YL, Kuriyama R, Erikson RL. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol 1995; 15:7143-51.
18. Uchiumi T, Longo DL, Ferris DK. Cell cycle regulation of the human polo-like kinase (PLK) promoter. J Biol Chem 1997; 272:9166-74. (Pubitemid 27154923)
19. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234:397-405. (Pubitemid 27243915)
20. St. Clair S, Giono L, Varmeh-Ziaie S, Resnick- Silverman L, Liu WJ, Padi A, et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 2004; 16:725-36. (Pubitemid 39586531)
21. van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005; 24:2844-59.
22. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279:25549-61. (Pubitemid 38756815)
23. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase 1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000; 2:672-6.
24. van Vugt MA, Smits VA, Klompmaker R, Medema RH. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. J Biol Chem 2001; 276:41656-60.
25. Incassati A, Patel D, McCance DJ. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6. Oncogene 2006; 25:2444-51.
26. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, et al. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 2004; 279:21183-92. (Pubitemid 38656522)
27. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009; 106:3964-9.
28. Zhu H, Chang BD, Uchiumi T, Roninson IB. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/ SDI1). Cell Cycle 2002; 1:59-66.
29. van Vugt MATM, Bras A, Medema RH. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell 2004; 15:799-811. (Pubitemid 39194909)
30. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501. (Pubitemid 28538613)
31. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8.
32. Bates GJ, Nicol SM, Wilson BJ, Jacobs AM, Bourdon JC, Wardrop J, et al. The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J 2005; 24:543-53. (Pubitemid 40343256)
33. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71:875-86.
34. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55 kD protein. Genes Dev 1994; 8:1235-46. (Pubitemid 24163450)
35. Hammond EM, Mandell DJ, Salim A, Krieg AJ, Johnson TM, Shirazi HA, et al. Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol 2006; 26:3492-504.
36. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247-57. (Pubitemid 34953189)
37. Lee KC, Crowe AJ, Barton MC. p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol 1999; 19:1279-88.
38. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65:2698-704. (Pubitemid 40490070)
39. Kreis NN, Sommer K, Sanhaji M, Kramer A, Matthess Y, Kaufmann M, et al. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle 2009; 8:460-72.
40. Liu X, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 2002; 99:8672-6. (Pubitemid 34693618)
41. Liu X, Erikson RL. Polo-like kinase (PLK)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-94. (Pubitemid 36576886)
42. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26:2093-108. (Pubitemid 43346913)
43. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94:1863-77. (Pubitemid 36104631)
44. Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002; 21:3162-71. (Pubitemid 34548087)
45. 2/M transition. Mol Biotechnol 2006; 32:227-48.
46. Young V, Ho M, Vosper H, Belch JJ, Palmer CN. Elevated expression of the genes encoding TNFalpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology 2002; 41:869-75.
47. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992; 101:183-9.
48. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 1998; 9:113-8. (Pubitemid 128472551)
49. Schumm K, Rocha S, Caamano J, Perkins ND. Regulation of p53 tumour suppressor target gene expression by the p52 NFkappaB subunit. EMBO J 2006; 25:4820-32. (Pubitemid 44607027)